

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM344520

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Intellectual Property Security Agreement Supplement		
SEQUENCE:	2		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Clinical Research Advantage, Inc.		06/11/2015	CORPORATION: ARIZONA
RECEIVING PARTY DATA			
Name:	Credit Suisse AG, Cayman Islands Branch, as Administrative Agent		
Street Address:	11 Madison Avenue		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10010		
Entity Type:	Bank: SWITZERLAND		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	3637316	CLINICAL RESEARCH ADVANTAGE	
Registration Number:	3597155	CLINICAL RESEARCH ADVANTAGE	
CORRESPONDENCE DATA			
Fax Number:	7147558290		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	714-540-1235		
Email:	ipdocket@lw.com		
Correspondent Name:	Latham & Watkins LLP		
Address Line 1:	650 Town Center Drive, Suite 2000		
Address Line 4:	Costa Mesa, CALIFORNIA 92626		
ATTORNEY DOCKET NUMBER:	051069-0002		
NAME OF SUBMITTER:	Anna T Kwan		
SIGNATURE:	/atk/		
DATE SIGNED:	06/12/2015		
Total Attachments: 11			
source=PPD - IP Security Agreement Supplement#page1.tif			
source=PPD - IP Security Agreement Supplement#page2.tif			

OP \$65.00 3637316

source=PPD - IP Security Agreement Supplement#page3.tif
source=PPD - IP Security Agreement Supplement#page4.tif
source=PPD - IP Security Agreement Supplement#page5.tif
source=PPD - IP Security Agreement Supplement#page6.tif
source=PPD - IP Security Agreement Supplement#page7.tif
source=PPD - IP Security Agreement Supplement#page8.tif
source=PPD - IP Security Agreement Supplement#page9.tif
source=PPD - IP Security Agreement Supplement#page10.tif
source=PPD - IP Security Agreement Supplement#page11.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT SUPPLEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT SUPPLEMENT (this "IP Security Agreement Supplement") dated June 11, 2015, is made by the Persons listed on the signature page hereof (each, a "Grantor" and collectively, the "Grantors") in favor of Credit Suisse AG, Cayman Islands Branch, as administrative agent (the "Administrative Agent") for the Secured Parties (as defined in the Credit Agreement referred to below).

WHEREAS, Jaguar Holding Company I, a Delaware corporation, Jaguar Holding Company II, a Delaware corporation, and Pharmaceutical Product Development, LLC, a Delaware limited liability company, have entered into the Credit Agreement dated as of December 5, 2011 (as amended, amended and restated, supplemented or otherwise modified from time to time, the "Credit Agreement"), with the Lenders, the Swing Line Lender, the L/C Issuers and the Administrative Agent. Terms defined in the Credit Agreement or in the Security Agreement (as defined below) and not otherwise defined herein are used herein as defined in the Credit Agreement or the Security Agreement, as the case may be (and in the event of a conflict, the applicable definition shall be the one given to such term in the Security Agreement).

WHEREAS, pursuant to the Credit Agreement, each Grantor has executed and delivered or otherwise become bound by that certain Security Agreement dated December 5, 2011 (as amended, amended and restated, supplemented or otherwise modified from time to time, the "Security Agreement") and that certain Intellectual Property Security Agreement dated December 5, 2011 (as amended, amended and restated, supplemented or otherwise modified from time to time, the "IP Security Agreement").

WHEREAS, under the terms of the Security Agreement, each Grantor has agreed to grant to the Administrative Agent, for the benefit of the Secured Parties, a security interest in any after-acquired intellectual property collateral of each such Grantor and has agreed in connection therewith to execute this IP Security Agreement Supplement for recording with the U.S. Patent and Trademark Office, the United States Copyright Office and other domestic governmental authorities.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantors agree as follows:

SECTION 1. Grant of Security. Each Grantor hereby grants to the Administrative Agent, for the benefit of the Secured Parties, a security interest in all of such Grantor's right, title and interest in and to the following (the "Additional Collateral"):

(i) the patents and patent applications set forth in Schedule A hereto (the "Patents");

(ii) the trademark and service mark registrations and applications set forth in Schedule B hereto (provided that no security interest shall be granted in United States intent-to-use trademark applications to the extent that, and solely during the period in which, the grant of a security interest therein would impair the validity or enforceability of such intent-to-use trademark applications under

applicable federal law), together with the goodwill symbolized thereby (the “Trademarks”);

(iii) the copyright registrations and applications and exclusive copyright licenses set forth in Schedule C hereto (the “Copyrights”);

(iv) all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the foregoing, all rights in the foregoing provided by international treaties or conventions, all rights corresponding thereto throughout the world and all other rights of any kind whatsoever of such Grantor accruing thereunder or pertaining thereto;

(v) any and all claims for damages and injunctive relief for past, present and future infringement, dilution, misappropriation, violation, misuse or breach with respect to any of the foregoing, with the right, but not the obligation, to sue for and collect, or otherwise recover, such damages; and

(vi) any and all proceeds of, collateral for, income, royalties and other payments now or hereafter due and payable with respect to, and supporting obligations relating to, any and all of the foregoing or arising from any of the foregoing;

provided that, notwithstanding anything to the contrary contained in the foregoing clauses (i) through (vi), the security interest created hereby shall not extend to, and the term “Additional Collateral,” shall not include any Excluded Property.

SECTION 2. Supplement to Security Agreement. Schedule III to the Security Agreement is, effective as of the date hereof, hereby supplemented to add to such Schedule the Additional Collateral.

SECTION 3. Security for Obligations. The grant of a security interest in the Additional Collateral by each Grantor under this IP Security Agreement Supplement secures the payment of all Secured Obligations of each such Grantor now or hereafter existing under or in respect of the Secured Documents (as such Secured Documents may be amended, amended and restated, supplemented, replaced, refinanced or otherwise modified from time to time (including any increases of the principal amount outstanding thereunder)), whether direct or indirect, absolute or contingent, and whether for principal, reimbursement obligations, interest, premiums, penalties, fees, indemnifications, contract causes of action, costs, expenses or otherwise. Without limiting the generality of the foregoing, this IP Security Agreement Supplement secures the payment of all amounts that constitute part of the Secured Obligations that would be owed by the Grantors to any Secured Party under the Secured Documents but for the fact that they are unenforceable or not allowable due to the existence of a bankruptcy, reorganization or similar proceeding involving a Loan Party.

SECTION 4. Recordation. Each Grantor authorizes and requests that the Register of Copyrights, the Commissioner for Patents and the Commissioner for Trademarks and any other applicable government officer to record this IP Security Agreement Supplement.

SECTION 5. Grants, Rights and Remedies. This IP Security Agreement Supplement has been entered into in conjunction with the provisions of the Security Agreement. Each Grantor does hereby acknowledge and confirm that the grant of the security interest hereunder to, and the rights and remedies of, the Administrative Agent with respect to the Additional Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated herein by reference as if fully set forth herein.

SECTION 6. Governing Law; Jurisdiction; Etc. (a) THIS IP SECURITY AGREEMENT SUPPLEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.

(b) EACH PARTY HERETO IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS PROPERTY, TO THE EXCLUSIVE JURISDICTION OF THE COURTS OF THE STATE OF NEW YORK SITTING IN THE STATE, COUNTY AND CITY OF NEW YORK AND OF THE UNITED STATES FOR THE SOUTHERN DISTRICT OF NEW YORK, AND ANY APPELLATE COURT FROM ANY THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS IP SECURITY AGREEMENT SUPPLEMENT, AND EACH OF THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY AGREES THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH NEW YORK STATE COURT OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN SUCH FEDERAL COURT. EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. NOTHING IN THIS IP SECURITY AGREEMENT SUPPLEMENT SHALL AFFECT ANY RIGHT THAT THE ADMINISTRATIVE AGENT, ANY LENDER OR ANY L/C ISSUER MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS IP SECURITY AGREEMENT SUPPLEMENT AGAINST THE BORROWERS OR ANY OTHER LOAN PARTY OR ITS PROPERTIES IN THE COURTS OF ANY JURISDICTION.


(c) EACH PARTY HERETO IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS IP SECURITY AGREEMENT SUPPLEMENT IN ANY COURT REFERRED TO IN PARAGRAPH (b) OF THIS SECTION. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT.

(d) EACH PARTY HERETO IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN SECTION 10.02 OF THE CREDIT AGREEMENT. NOTHING IN THIS IP SECURITY AGREEMENT SUPPLEMENT WILL AFFECT THE RIGHT OF ANY PARTY HERETO TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY APPLICABLE LAW.


(e) EACH PARTY TO THIS IP SECURITY AGREEMENT SUPPLEMENT HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION OR CAUSE OF ACTION ARISING UNDER THIS IP SECURITY AGREEMENT SUPPLEMENT OR IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO OR ANY OF THEM WITH RESPECT TO THIS IP SECURITY AGREEMENT SUPPLEMENT, OR THE TRANSACTIONS RELATED THERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER FOUNDED IN CONTRACT OR TORT OR OTHERWISE; AND EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY, AND THAT ANY PARTY TO THIS AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION 6(E) WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE SIGNATORIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.

IN WITNESS WHEREOF, each Grantor has caused this IP Security Agreement Supplement to be duly executed and delivered by its officer thereunto duly authorized as of the date first written above.


CLINICAL RESEARCH ADVANTAGE, INC.

By: 
Name: B. Judd Hartman
Title: General Counsel and Secretary


CNS RESEARCH SCIENCE, INC.

By: 
Name: B. Judd Hartman
Title: General Counsel and Secretary

RADIANT RESEARCH, INC.

By: 
Name: B. Judd Hartman
Title: General Counsel and Secretary

X-CHEM, INC.

By: 
Name: B. Judd Hartman
Title: Vice President, General Counsel and Secretary

PHARMACO INVESTMENTS, INC.

By: 
Name: B. Judd Hartman
Title: President

Address for notices:
929 North Front Street
Wilmington, NC 28401
Attention: General Counsel
(P) 910.558.6928
(F) 910.558.6951
(E) Judd.Hartman@ppdi.com

Schedule A
Intellectual Property Security Agreement Supplement

U.S. Patents

Grantor	Country	Patent Title	Application No. Filing Date	Patent No. Issue Date
ISSUED				
Pharmaco Investments, Inc.	United States	Microtiter Plate System and Method	13/584,414 13Aug12	8,790,599 29Jul14
Pharmaco Investments, Inc.	United States	Microtiter Plate System and Method	13/584,414 13Aug12	8,790,599 29Jul14
APPLICATIONS				
X-Chem, Inc.	United States	METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES	61/152,508 2/13/2009	N/A
X-Chem, Inc.	United States	METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES	13/147,910 8/04/2011	N/A
X-Chem, Inc.	United States	METHODS FOR TAGGING DNA-ENCODED LIBRARIES	61/531,820 9/07/2011	N/A
X-Chem, Inc.	United States	METHODS FOR TAGGING DNA-ENCODED LIBRARIES	61/536,929 9/20/2011	N/A
X-Chem, Inc.	United States	METHODS FOR TAGGING DNA-ENCODED LIBRARIES	14/343,306 03/06/2014	N/A
X-Chem, Inc.	United States	DNA-ENCODED LIBRARIES HAVING ENCODING OLIGONUCLEOTIDE LINKAGES NOT READABLE BY POLYMERASES	61/671,406 7/13/2012	N/A
X-Chem, Inc.	United States	DNA-ENCODED LIBRARIES HAVING SITES FOR REVERSIBLE IMMOBILIZATION	61/901,899 11/08/ 2013	N/A
X-Chem, Inc.	United States	SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND USES THEREOF	62/043,275 8/28/2014	N/A
X-Chem, Inc.	United States	DNA-ENCODED LIBRARIES HAVING ENCODING OLIGONUCLEOTIDE LINKAGES NOT READABLE BY POLYMERASES	14/414,326 1/12/2015	N/A
X-Chem, Inc.	United States	METHODS FOR TAGGING DNA-ENCODED LIBRARIES	62/098,037	N/A

Schedule B
Intellectual Property Security Agreement Supplement

U.S. Trademarks

Grantor	Country	Mark	Application No. Filing Date	Registration No. Registration Date
U.S. ISSUED				
Pharmaco Investments, Inc.	United States	PRECLARUS	86088574 10/10/13	4,573,756 7/22/2014
Clinical Research Advantage, Inc.	United States	CLINICAL RESEARCH ADVANTAGE	77247167 08/03/2007	3637316 06/16/2009
Clinical Research Advantage, Inc.	United States	CLINICAL RESEARCH ADVANTAGE	77247158 08/03/2007	3597155 03/31/2009
Radiant Research, Inc.	United States	RADIANT RESEARCH	75578547 10/28/1998	2511395 11/27/2001
CNS Research Science, Inc.	United States	CNS	78934084 07/20/2006	3431297 05/20/2008
CNS Research Science, Inc.	United States	CNS	78934095 07/20/2006	3431298 05/20/2008
CNS Research Science, Inc.	United States	CNS	78934103 07/20/2006	3431299 05/20/2008
CNS Research Science, Inc.	United States	CNS	78934123 07/20/2006	3431300 05/20/2008
CNS Research Science, Inc.	United States	CNS COMPREHENSIVE NEUROSCIENCE	77547388 08/14/2008	3966684 08/24/2011
CNS Research Science, Inc.	United States	CNS COMPREHENSIVE NEUROSCIENCE	77547401 08/14/2008	3962188 05/17/2011
CNS Research Science, Inc.	United States	CNS COMPREHENSIVE NEUROSCIENCE	77547413 08/14/2008	3962189 05/17/2011
CNS Research Science, Inc.	United States	CNS COMPREHENSIVE NEUROSCIENCE	77547419 08/14/2008	3962190 05/17/2011
CNS Research Science, Inc.	United States	CNS COMPREHENSIVE NEUROSCIENCE	77547432 08/14/2008	3966685 05/24/2011
CNS Research Science, Inc.	United States	CNS COMPREHENSIVE NEUROSCIENCE	77547437 08/14/2008	4084213 01/10/2012

Grantor	Country	Mark	Application No. Filing Date	Registration No. Registration Date
CNS Research Science, Inc.	United States	CNS COMPREHENSIVE NEUROSCIENCE	78934129 07/20/2006	3449533 06/17/2008
CNS Research Science, Inc.	United States	CNS COMPREHENSIVE NEUROSCIENCE	78934134 07/20/2006	3449534 06/17/2008
CNS Research Science, Inc.	United States	CNS COMPREHENSIVE NEUROSCIENCE	78934139 07/20/2006	3449535 06/17/2008
CNS Research Science, Inc.	United States	CNS COMPREHENSIVE NEUROSCIENCE	78934161 07/20/2006	3449536 06/17/2008
CNS Research Science, Inc.	United States	COMPREHENSIVE CLINICAL DEVELOPMENT	85348733 06/17/2011	4156802 06/12/2012
CNS Research Science, Inc.	United States	COMPREHENSIVE CLINICAL DEVELOPMENT	85348738 06/17/2011	4156803 06/12/2012
CNS Research Science, Inc.	United States	COMPREHENSIVE CLINICAL DEVELOPMENT	85348740 06/17/2011	4156804 06/12/2012
CNS Research Science, Inc.	United States	COMPREHENSIVE CLINICAL DEVELOPMENT	85201170 12/17/2012	4155886 06/05/2012
CNS Research Science, Inc.	United States	COMPREHENSIVE CLINICAL DEVELOPMENT	85201172 12/17/2010	4148011 05/22/2012
CNS Research Science, Inc.	United States	COMPREHENSIVE CLINICAL DEVELOPMENT	85201174 12/17/2010	4155887 06/05/2012
CNS Research Science, Inc.	United States	COMPREHENSIVE NEUROSCIENCE	78934029 07/20/2006	3500478 09/09/2008
CNS Research Science, Inc.	United States	COMPREHENSIVE NEUROSCIENCE	78934045 07/20/2006	3500479 09/09/2008
CNS Research Science, Inc.	United States	COMPREHENSIVE NEUROSCIENCE	78934053 07/20/2006	3500480 09/09/2008
CNS Research Science, Inc.	United States	COMPREHENSIVE NEUROSCIENCE	78934060 07/20/2006	3500781 09/09/2008
CNS Research Science, Inc.	United States	COMPREHENSIVE NEUROSCIENCE	78934071 07/20/2006	3500482 09/09/2008
CNS Research Science, Inc.	United States	COMPREHENSIVE NEUROSCIENCE	78934077 07/20/2006	3500483 09/08/2008

Grantor	Country	Mark	Application No. Filing Date	Registration No. Registration Date
---------	---------	------	--------------------------------	---------------------------------------

U.S. APPLICATIONS

Pharmaco Investments, Inc.	United States	TRIMENTUM	86303607 6/09/14	N/A
----------------------------	---------------	-----------	---------------------	-----

Schedule C
Intellectual Property Security Agreement Supplement

U.S. Copyrights

None.